Diagnostic Pathology

Table 1 Clinical features of the 69 SGMN patients

From: CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms

		Male		Female		Total
			%		%		%
Gender		28	40.6	41	59.4	69	100.00
Age	≤ 60	19	27.5	22	31.9	41	59.3
	> 60	9	13.0	19	27.5	28	40.7
Smoking intake	Yes	14	20.3	9	13.0	23	33.3
	No	14	20.3	32	46.4	46	66.7
Alcohol intake	Yes	9	13.0	5	7.2	14	20.3
	No	19	27.5	36	52.2	55	70.3
Disease Classification	MC	7	10.1	4	5.8	11	15.9
	ACC	11	15.9	23	33.3	34	49.3
	ACA	1	1.4	3	4.3	4	5.8
	A.(nos)	4	5.8	1	1.4	5	7.2
	BCA	2	2.9	3	4.3	5	7.2
	PLGA	2	2.9	1	1.4	3	4.3
	Cex-PA	0	0.0	4	5.8	4	5.8
	SDC	1	1.4	2	2.9	3	4.3
PLS^a	PG^b	10	14.5	17	24.6	26	37.7
	SubM.G^c	8	11.6	5	7.2	13	18.8
	SubL.G^d	0	0.0	2	2.9	2	2.9
	MinorG^e	10	14.5	17	24.6	27	39.1
Tumor Size	T1	5	7.2	20	30.0	25	36.2
	T2	12	17.4	5	7.2	17	24.6
	T3	5	7.2	11	15.9	16	23.2
	T4	6	8.7	5	7.2	11	15.9
Clinical Stage	I	2	2.9	14	20.3	16	23.2
	II	7	10.1	1	1.4	8	11.6
	III	2	2.9	9	13.0	11	15.9
	VI	17	24.6	17	24.6	34	49.3
Treatment	Surgery	5	7.2	14	20.3	19	27.5
	S. RT	11	15.9	19	27.5	30	43.5
	S. CT.	3	4.3	1	1.4	4	5.8
	S. RT and CT	9	13.0	7	10.1	16	23.2
Lymph node	Negative	24	34.8	34	49.3	58	84.1
	Positive	4	5.8	7	10.1	11	15.9
Metastasis	No	15	21.7	28	40.6	43	62.3
	Yes	13	18.8	13	18.8	26	37.7
Loco-regional	No	17	24.6	28	40.6	45	65.2
recurrence	Yes	11	15.9	13	18.8	24	34.8
Death	No	15	21.7	33	47.8	48	69.6
	Yes	13	18.8	8	11.6	21	30.4

RT: Radiotherapy; CT: Chemotherapy; ^a PLS: Primary Lesion Site; ^b PG: Parotid Gland; ^c SubM.G: Submandibular Gland; ^d SubL.G: Sublingual Gland; ^e MinorG: Minor Salivary Glands. MC: mucoepidermoid carcinoma; ACC: adenoid cystic carcinoma; ACA: acinic cell adenocarcinoma; A (nos): adenocarcinoma; Cex-PA: carcinoma ex-pleomorphic adenoma; SDC: salivary duct carcinoma; PLGA: polymorphous low-grade adenocarcinoma; BCA: basal cell adenocarcinoma (BCA); MMN: malignant myoepithelial neoplasm.

Back to article page

ISSN: 1746-1596

Contact us

Submission enquiries: journalsubmissions@springernature.com